Dana-Farber Cancer Institute | Strategic Alliance Partners

August 23, 2024

Adrienne G. Waks, MD, discusses efforts to improve treatment outcomes for patients with HER2-positive breast cancer with residual disease.

August 23, 2024

Karl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.

August 22, 2024

In 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses.

August 22, 2024

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

August 22, 2024

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

August 22, 2024

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

August 22, 2024

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

August 22, 2024

Emre Yekedüz, MD, discusses a case study shared via an OncLive X poll on the adjuvant treatment of clear cell renal cell carcinoma.

August 21, 2024

Praful K. Ravi, MB, BChir, MRCP, discusses the prognostic impact of residual cancer burden on long-term outcomes in high-risk localized prostate cancer.

August 21, 2024

Bradley McGregor, MD, discusses the future implications of evolutions in the renal cell carcinoma treatment paradigm.

August 20, 2024

Sara M. Tolaney, MD, MPH, discusses standard frontline treatment approaches for patients with HER2-positive breast cancer.

August 20, 2024

Bradley McGregor, MD, discusses the clinical implications of the DAD-IO trial in patients with metastatic urothelial carcinoma.

August 19, 2024

Renee Saliby, MD, MSc, discusses the investigation of the correlation between intermediate end points and OS in metastatic renal cell carcinoma.

August 18, 2024

Andrew Hantel, MD, discusses environmental and health impacts of decentralizing cancer care in response to high emissions generated by US health care.

August 16, 2024

Andrew Hantel, MD, discusses the evaluation of eligibility criteria in acute myeloid leukemia clinical trials that may perpetuate racial disparities.

August 16, 2024

Renee Maria Saliby, MD, MS, discusses potential intermediate end points for overall survival in previously treated metastatic renal cell carcinoma.

August 15, 2024

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

August 15, 2024

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

August 15, 2024

Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.

August 15, 2024

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.